|
|
Article: Forecasting company predicts anticholesterol market share for Vytorin.
- Article from:
- Biotech Business Week
- Article date:
- August 30, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 AUG 30 - (NewsRx.com & NewsRx.net) -- Princeton Brand Econometrics (PBE) forecasts a maximum potential 11.7% share of the anticholesterol market for Vytorin, a joint-venture product of Schering-Plough Corporation (NYSE: SGP) and Merck & Co., Inc. (NYSE: MRK) that was approved last month by the U.S. Food and Drug Administration.
Vytorin combines two anticholesterol agents, Zocor, sold by Merck, and Zetia, jointly sold by both companies. Merck/Schering-Plough Pharmaceuticals claims that the new combination results in dramatic decreases in LDL (bad cholesterol) without meaningful increases in side effects. The lowest dose of Vytorin has been found to be more ...